Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALPL | P05186 | 2/20 | 0.62 |
| ▸ | ALPI | P09923 | 2/20 | 0.62 |
| ▸ | ALPG | P10696 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10955756 | 0.98 | PKM (0.61) | PKMRECQLKMT2AALPLALPI | |
| SCHEMBL27536631 | 0.93 | CYP1A2 (0.64) | PKMRECQLKMT2AALPLALPI | |
| SCHEMBL17775464 | 0.86 | ALOX15 (0.59) | PKMRECQLKMT2AMEN1ALOX15 | |
| SCHEMBL4422103 | 0.86 | MEN1 (0.66) | PKMRECQLKMT2AMEN1GAA | |
| SCHEMBL10903296 | 0.83 | KMT2A (0.67) | KMT2AALPLALPIALPGMEN1 | |
| SCHEMBL6539261 | 0.83 | PLA2G4B (0.60) | PKMRECQLKMT2AMEN1ALOX15 | |
| SCHEMBL20325853 | 0.83 | RAB9A (0.51) | PKMRECQLALOX15NPC1RAB9A | |
| SCHEMBL171840 | 0.82 | MEN1 (0.61) | PKMRECQLKMT2AMEN1HPGD | |
| SCHEMBL13916156 | 0.82 | KMT2A (0.54) | PKMRECQLKMT2AMEN1NPC1 | |
| SCHEMBL4427417 | 0.82 | PKM (0.54) | PKMRECQLKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2022106669-A1 | NEW PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3515455-B1 | COMPOUNDS FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | UNIV AARHUS (DK) | 2021-04-14 | — | — | EP | disclosed |
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-4958018-A | REACTING A 3-HALOMETHYL-3-CEPHEM WITH A LEAD REDUCING AGENT | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-09-18 | — | — | US | disclosed |
| US-4524028-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1985-06-18 | — | — | US | disclosed |
| US-4518533-A | Azetidinone-4-disulfides as intermediates for thia-aza compounds with a beta-lactam ring | CIBA GEIGY CORPORATION (US) | 1985-05-21 | — | — | US | disclosed |
| US-4515717-A | INTERMEDIATES FOR 6-UNSUBSTITUTED PENICILLIN ANTIOBIOTICS | CIBA GEIGY CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
| US-4500457-A | TREATING AN ACYLOXYAZETIDINONE WITH MERCAPTO COMPOUND, GLYOYLIC ESTER, HALOGENATION AGENT, AND PHOSPHINE COMPOUNT THEN CYCLIZATION | CIBA-GEIGY CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| US-4447360-A | Intermediates for thia-aza compounds with a β-lactam ring | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | disclosed |
| US-4331676-A | 2-PENEM COMPOUNDS UNSUBSTITUTED IN THE 6 POSITION | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| US-4234488-A | FLUORESCENT DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| US-4147865-A | Benz-(C,D)-indolyl compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | PKM 2847/4885RECQL 3056/4885KMT2A 4666/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | PKM 4093/4885RECQL 3533/4885KMT2A 3472/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | PKM 3226/4885RECQL 3360/4885KMT2A 4741/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | PKM 2847/4885RECQL 3056/4885KMT2A 4666/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | PKM 2847/4885RECQL 3056/4885KMT2A 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.